Tumors of the Central Nervous System, Volume 2

Chapter 1.
INTRODUCTION. I.
BIOMARKERS AND DIAGNOSIS. Chapter 2.
GLIOMAGENESIS: ADVANTAGES AND LIMITATIONS OF BIOMARKERS.
Chapter 3.
MOLECULAR SUBTYPES OF GLIOMAS.
Chapter 4.
GLIOBLASTOMA: GERMLINE MUTATION OF
TP53. Chapter 5.
GLIOMAS: ROLE OF THE
TP53
GENE.
Chapter 6.
THE ROLE OF IDH1 AND IDH2 MUTATIONS IN MALIGNANT GLIOMAS.
Chapter 7.
MALIGNANT GLIOMA: ISOCITRATE DEHYDROGENASES 1 AND 2 MUTATIONS.
Chapter 8.
METABOLIC DIFFERNCES IN DIFFERENT REGIONS OF GLIOMA SAMPLES.
Chapter 9.
GLIOBLASTOMA PATIENTS: ROLE OF METHYLATED MGMT.
Chapter 10
. BRAIN TUMOR ANGIOGENESIS AND GLIOMA GRADING: ROLE OF TUMOR BLOOD VOLUME AND PERMEABILITY ESTIMATES USING PERFUSION CT.
Chapter 11.
VASCULOGENIC MIMICRY IN GLIOMA.
Chapter 12.
NEWLY DIAGNOSED GLIOMA: DIAGNOSIS USING POSITRON EMISSION TOMOGRAPHY WITH METHIONINE AND FLUOROTHYMIDINE.
Chapter 13.
ROLE OF DIFFUSION TENSOR IMAGING IN DIFFERENTIATION OF GLIOBLASTOMAS FROM SOLITARY BRAIN METASTASES.
Chapter 14.
I-TM-601 SPECT IMAGING OF HUMAN GLIOMA.
Chapter 15.
ASSESSMENT OF BIOLOGICAL TARGET VOLUME USING POSITRON EMISSION TOMOGRAPHY IN HIGH-GRADE GLIOMA PATIENTS.
Chapter 16.
SKIN METASTASES OF GLIOBLASTOMA. II.
THERAPY. Chapter 17.
DIFFUSE LOW-GRADE GLIOMAS. WHAT DOES COMPLETE RESECTION MEAN?
Chapter 18.
QUANTITATIVE APPROACH OF THE NATURAL COURSE OF DIFFUSE LOW-GRADE GLIOMAS.
Chapter 19.
IMPACT OF RESECTION EXTENT ON OUTCOMES IN PATIENTS WITH HIGH-GRADE GLIOMAS.
Chapter 20.
RECURRENT MALIGNANT GLIOMAS: 5-AMINOLEVULINIC ACID FLUORESCENCE-GUIDED RESECTION.
Chapter 21.
GLIOMA SURGERY: INTRAOPERATIVE LOW FIELD MAGNETIC RESONANCE IMAGING.
Chapter 22.
LOW-GRADE GLIOMAS: INTRAOPERATIVE ELECTRICAL STIMULATIONS.
Chapter 23.
MALIGNANT GLIOMAS: PRESENT AND FUTURE THERAPEUTIC DRUGS.
Chapter 24.
RECURRENT MALIGNANTGLIOMA PATIENTS: TREATMENT WITH CONFORMAL RADIOTHERAPY AND SYSTEMIC THERAPY.
Chapter 25.
GLIOBLASTOMA: BORON NEUTRON CAPTURE THERAPY.
Chapter 26.
GLIOBLASTOMA: ANTI-TUMOR ACTION OF CYCLOSPORINE A AND FUCTIONALLY RELATED DRUGS. Chapter 27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE.
Chapter 28.
GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE.
Chapter 29.
GLIOMA-INITIATING CELLS: INTERFERON TREATMENT.
Chapter 30.
GLIOBLASTOMA : ANTITUMOR ACTION OF NATURAL AND SYNTHETIC CANNABINOIDS.
Chapter 31.
PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN.
Chapter 32.
MONITORING GLIOMAS
IN VIVO
USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY INDUCED APOPTOSIS.
Chapter 33.
HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY.
Chapter 34.
GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS.
Chapter 35.
FISCHER-F98 GLIOMA MODEL: METHODOLOGY.
Chapter 36.
CELLULAR CHARACTERIZATION OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL GLIOMA.
Chapter 37.
ADULT BRAINSTEM GLIOMAS: DIAGNOSIS AND TREATMENT .
Chapter 38
. USE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS. III.
PROGNOSIS. Chapter 39.
BRAINSTEM GLIOMAS: AN OVERVIEW.
Chapter 40.
TUMOR-ASSOCIATED EPILEPSY IN PATIENTS WITH GLIOMA.
Chapter 41.
CHRONIC EPILEPSY ASSOCIATED WITH BRAIN TUMORS: SURGICAL NEUROPATHOLOGY.
Chapter 42.
LOW-GRADE GLIOMAS: ROLE OF RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION.
Chapter 43.
ANGIOCENTRIC GLIOMA- INDUCED SEIZURES: LESIONECTOMY.